First and second-trimester biochemical markers of chromosomal anomalies and their relationship to maternal haemoglobin levels

Cowans, Nicholas J.; Spencer, Kevin

doi:10.1002/pd.1191

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our data, levels of maternal serum free b-hCG and PAPP-A and ultrasound fetal nuchal translucency thickness were not influenced by maternal hepatitis B carrier status. This finding stands in contrast to the results found for other maternal factors such as body weight, 3 ethnicity, 2 smoking, 4 consanguinity, 12 hemoglobin level, 13 use of assisted reproductive technology, 6 and HIV carrier status. 14 No definite explanation is currently available for discrepancies in levels of maternal serum markers based on maternal factors.…”

Section: Discussioncontrasting

confidence: 97%

Effect of Maternal Hepatitis B Carrier Status on First-Trimester Markers of Down Syndrome

et al. 2010

View full text Add to dashboard Cite

Up to 10% of women of reproductive age in our country are carriers of hepatitis B virus. This study examined whether maternal hepatitis B carrier status has any effect on markers used in first-trimester screening for Down syndrome. Records for 2 major Taiwanese hospitals were retrospectively examined to identify women with singleton pregnancies resulting in normal live births from June 2002 through 2008. Maternal hepatitis B data were used to define 3 groups: seronegative women, inactive carrier women, and active carrier women. Women with active or inactive carrier status were significantly older than seronegative women. The results of the study show that maternal hepatitis B carrier status does not influence first-trimester levels of maternal serum free beta-human chorionic gonadotropin (free beta-hCG) multiples of the median (MoM), pregnancy-associated plasma protein A (PAPP-A) MoM, and median fetal nuchal translucency and screening false-positive rate; therefore, correction in the risk calculation algorithm for maternal hepatitis B carrier status is not necessary.

show abstract

Section: Discussioncontrasting

confidence: 97%

Effect of Maternal Hepatitis B Carrier Status on First-Trimester Markers of Down Syndrome

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In cases of alloimmunized pregnancies with fetal anemia, measured MS-AFP elevations preceded the presence of increased Doppler velocity by nearly 3 weeks. In contrast to the previous report, another group reported that both first-and second-trimester biochemical markers of trisomies had no relationship to maternal hemoglobin concentrations; however, Doppler velocity measurements were not done in this instance (116). Finally, the application of Doppler methodology to the analysis of factors predicting antepartum stillbirth was studied in conjunction with MS-AFP and pregnancy-associated plasma protein-A (PAPP-A) levels (117).…”

Section: Adverse Pregnancy Complications/outcomes Related To Hafpmentioning

confidence: 94%

Physiology of Alpha-Fetoprotein as a Biomarker for Perinatal Distress: Relevance to Adverse Pregnancy Outcome

Mizejewski

2007

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

The many physiologic roles of human alpha-fetoprotein (HAFP) and its correlation with perinatal distress/pregnancy outcome are rarely addressed together in the biomedical literature, even though HAFP has long been used as a biomarker for fetal birth defects. Although the well being of the fetus can be monitored by the measurement of gestational age-dependent HAFP in biologic fluid levels (serum, amniotic fluid, urine, and vaginal fluids) throughout pregnancy, the majority of clinical reports reflect largely second trimester and (less likely) first trimester testing due to regulatory clinical restrictions. However, reports of third-trimester and pregnancy term measurement of HAFP levels performed in clinical research and/or investigational settings have gradually increased over the years and have expanded our base knowledge of AFP-associated pregnancy disorders during these stages. The different structural forms of HAFP (isoforms, epitopes, molecular variants, etc.) detected in the various biologic fluid compartments have been limited by antibody recognition of specific epitopic sites developed by the kit manufacturers based on antibody specificity, sensitivity, and precision. Concomitantly, the advances in elucidating the various biologic actions of AFP are opening new vistas toward understanding the physiologic roles of AFP during pregnancy. The present review surveys HAFP as a biomarker for fetal distress during the perinatal period in view of its structural and functional properties. An attempt is then made to relate the AFP fluid levels to adverse pregnancy complications and outcomes. Hence, the present review was divided into two major sections: (I) AFP structure and function considerations and (II) the relationship of AFP levels to the distressed fetus during the third trimester and at term.

show abstract

Current awareness in prenatal diagnosis

2005

Prenat. Diagn.

View full text Add to dashboard Cite

First and second-trimester biochemical markers of chromosomal anomalies and their relationship to maternal haemoglobin levels

Abstract: There is no relationship between maternal haemoglobin levels and the levels of Down syndrome markers in either the first or second trimester. Biochemical marker levels do not need to be corrected for haemoglobin concentrations when used in screening for Down syndrome.

Cited by 3 publications

References 21 publications

Effect of Maternal Hepatitis B Carrier Status on First-Trimester Markers of Down Syndrome

Effect of Maternal Hepatitis B Carrier Status on First-Trimester Markers of Down Syndrome

Physiology of Alpha-Fetoprotein as a Biomarker for Perinatal Distress: Relevance to Adverse Pregnancy Outcome

Current awareness in prenatal diagnosis

Contact Info

Product

Resources

About